Return to content in this issue


Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia

Sato H, Miyata Y, Inoue H, Tanaka A, Sagara H

Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan

J Investig Allergol Clin Immunol 2021; Vol 31(5) : 459-460
doi: 10.18176/jiaci.0671

Key words: Chronic eosinophilic pneumonia, Mepolizumab, Anti-IL-5 monoclonal antibody, Asthma, Extended interval dosing

Title Type Size
10.18176_jiaci.0671_suppl-material_1.pdf pdf 273.54 Kb